Clinuvel Pharmaceuticals

We are a global biopharmaceutical company committed to developing drugs for the treatment of a range of severe skin disorders.

Clinuvel’s lead compound, SCENESSE® (afamelanotide 16mg), a first-in-class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe. In December 2014 the European Commission granted SCENESSE® marketing authorisation under exceptional circumstances for the prevention of phototoxicity in adult patients with EPP. Further trials of SCENESSE® are underway in the pigmentary disorder vitiligo.

Our website has been developed to help share our expertise on the interaction of light and human skin as well as provide a thorough overview of our global drug development programs.

Latest Company Announcements

Breakthrough treatment for orphan genetic disorder presented to the general medical community EXECUTIVE SUMMARY SCENESSE® published as innovative treatment in erythropoietic protoporphyria (EPP) Combined analyses of Phase III studies show significant improvement in the duration of patient sun exposure without phototoxicity New England Journal of Medicine: highest “impact factor” medical journal Pivotal studies led to December 2014 European marketing authorisation Melbourne, Australia and Leatherhead, UK Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that results from its pivotal Phase III studies of SCENESSE® (afamelanotide 16mg) in the orphan genetic disorder erythropoietic protoporphyria (EPP) have been published in the New England Journal of Medicine (NEJM, 2015, vol 375: 48-59, publisher’s embargo lifted at 17:00 EST, July 1). COMMENTARY “Despite more than 40 years in the field it was only while participating as a senior physician in trials with afamelanotide that I gained insight into the major restrictions that EPP places on the daily activities of patients,” said Prof Paul Wilson, Emeritus Professor of Internal Medicine, Netherlands Porphyria Centre, Erasmus MC Rotterdam, and senior co-author of the NEJM paper. “The effect of afamelanotide on diminishing these restrictions and on patient quality of life is dramatic – even more dramatic than has been captured by the trial assessment tools – and a great advantage of the drug is that side effects are minimal.” “The approval of afamelanotide by the European Commission following these trial results represents a major breakthrough for EPP patients. As European porphyria physicians we now enter the next phase of making the drug available to our adult patients,” Prof Wilson said. “The trial results show that the afamelanotide treatment transforms the lives of EPP patients, in essence that is the ultimate goal of having a company and academia working on new technology for 10 years,” said Dr Robert J Desnick, Dean for Genetic and Genomic Medicine and Professor and Chairman Emeritus of the Department of Genetics and Genomic Sciences at Mount Sinai School of Medicine, New York, and the corresponding author for the NEJM paper. “I’m optimistic that afamelanotide will be available to US patients in the future and delighted that European patients will soon have access to a much-needed treatment.” “Today’s publication in the NEJM is as big an event for physicians as it is for patients: the most prestigious medical journal acknowledges a cutting-edge treatment for light-intolerant patients. Beyond EPP there is a great deal of potential for afamelanotide and similar melanocortin-based therapies. The immediate and most obvious targets are translationally photosensitive and light-induced disorders where no effective therapeutic options exist,” Dr Desnick said. “To evaluate SCENESSE® as an innovative drug in EPP, we worked closely with the world’s leading EPP experts to develop the clinical trials’ designs and assessment tools to assess the benefits of this treatment for patients,” Clinuvel’s Director Clinical Affairs, Dr Emilie Rodenburger said. “By measuring the symptom free time patients could spend in direct light, we sought to evaluate the impact treatment with SCENESSE® could have on enabling a normal, risk-free life. Despite all the challenges faced, I am very pleased for all patients and physicians that we persevered.” “The lead NEJM authors, Drs Langendonk and Balwani, deserve particular recognition for their initiative and expertise in rare and metabolic disorders,” Dr Rodenburger said. ANALYSES OF CUV029 AND CUV039 IN NEJM The NEJM article, “Afamelanotide for Erythropoietic Protoporphyria”, reviewed results from two Phase III studies, CUV029 (Europe) and CUV039 (US) conducted across 15 specialist centres. Combined analyses of 168 EPP patients showed that SCENESSE® enabled those who received active drug to expose their skin to daylight and sun without incurring characteristic phototoxic burns, with statistically significant longer exposure seen in patients who received the active drug (p=0.04 in the US, p=0.005 in Europe). The quality of life of patients measured by an EPP-specific survey was compared between active and placebo recipients. The group receiving SCENESSE® showed marked improvement of quality of life at various time points (range of p The NEJM authors emphasised difficulties of evaluating a novel treatment in EPP, a disease which had not previously been subject to parallel placebo-controlled randomised clinical trials. Both studies evaluated the safety of SCENESSE®. Treatment-emergent adverse events – those considered related to afamelanotide – were mild or moderate in severity with no serious treatment-related adverse events identified. The NEJM authors concluded that “afamelanotide had an acceptable side-effect profile and improved tolerance to sunlight in patients with erythropoietic protoporphyria”. RELEVANCE OF SCENESSE® IN THE TREATMENT OF EPP EPP is a particularly complex genetic disorder. Patients experience intense fear of incurring phototoxicity due to light exposure; severe dermal burns can result from any exposure to light, resulting in prolonged distress and incapacitation. The visible wavelengths of light cause the characteristic phototoxicity. From childhood onwards EPP patients are forced to isolate themselves from all sun and light exposure. The ingrained behaviour to minimise light exposure dictates EPP patients’ lives. Afamelanotide, the active ingredient in SCENESSE®, acts as an agonist to the melanocortin-1 receptor and is part of the family of drugs known as melanocortins. SCENESSE® delivers 16mg of afamelanotide as a controlled-release implant activating the pathway to stimulate melanin in skin. As a result patients’ skin becomes visibly darker as soon as 48 hours after drug administration. Melanin reduces skin damage from light exposure by acting as an umbrella over cells. Afamelanotide and melanin also act as powerful antioxidants. As previously reported by Clinuvel, the majority of patients who received SCENESSE® have expressed that the drug provided them a freedom to lead a life they had not had before, enabling them to participate in outdoor activities without fear of severe incapacitating symptoms. EUROPEAN MARKET ACCESS SCENESSE® Based on all five EPP studies conducted with afamelanotide, in particular CUV029 and CUV039, SCENESSE® was granted European marketing authorisation on 22 December 2014 for adult EPP patients. The drug will be made available to European EPP patients as soon as the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee has reviewed the Central European EPP Disease Registry. NEW ENGLAND JOURNAL OF MEDICINE (NEJM) The NEJM currently has the highest impact factor (54.42 in 2013/14) of all medical periodicals, an independent measure reflecting the frequency of citations of its publications. The NEJM’s published articles are subject to rigorous peer review. An earlier open-label study of SCENESSE® in EPP patients was published in the NEJM in 2009. CLINUVEL CONTRIBUTION In accordance with the NEJM Ingelfinger Rule, none of the article on both trials in EPP has been previously published in a medical journal. Although both clinical trials were sponsored by Clinuvel Pharmaceuticals, Clinuvel was not involved in the writing or editing of the manuscript. Clinuvel does not financially incentivise physicians or academics to publish its clinical trial results. REFERENCES Langendonk JG et al (2015). Afamelanotide for Erythropoietic Protoporphyria. New Eng J Med. 373(1):48-59. Abstract online at   http://www.nejm.org/doi/full/10.1056/NEJMoa1411481. Harms J, Minder EI & Minder CE (2009). An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria. New Eng J Med, 360(3):306-307. - End - Media note: Dr Robert J Desnick is available for interview through the Press Office at Mount Sinai School of Medicine, please contact Sid Dinsay via +1 212 241 9200 or This email address is being protected from spambots. You need JavaScript enabled to view it. . Media enquiries Lachlan Hay, Clinuvel (UK) Ltd. +44 1372 860 765     This email address is being protected from spambots. You need JavaScript enabled to view it. Nick Miles, Cabinet Privé de Conseils s.a. +41 22 321 4540     This email address is being protected from spambots. You need JavaScript enabled to view it. Ted Agne, The Communications Strategy Group Inc. +1 718 631 3117    This email address is being protected from spambots. You need JavaScript enabled to view it. Emma Power, Monsoon Media +61 3 9620 3333     This email address is being protected from spambots. You need JavaScript enabled to view it. Investor enquiries    This email address is being protected from spambots. You need JavaScript enabled to view it. About Clinuvel Pharmaceuticals Limited Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe disorders. With its unique expertise in understanding the interaction of light and human skin, the company has identified patient populations with a clinical need for photoprotection and another population with a need for repigmentation. These patient groups range in size from 5,000 to 45 million. Clinuvel’s lead compound, SCENESSE® (afamelanotide 16mg), a first-in-class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe, and has been approved by the European Commission for treating adults with EPP. Headquartered in Melbourne, Australia, Clinuvel has operations in Europe, the US and Singapore. For more information go to   http://www.clinuvel.com. Clinuvel is an Australian biopharmaceutical company focussed on developing its drug SCENESSE® (afamelanotide 16mg) for a range of clinical disorders with unmet need. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following: actual results may and often will differ materially from these forward-looking statements; no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for SCENESSE® can or will be achieved; no assurances can be given by Clinuvel that, even if its development programme for SCENESSE® is successful, it will obtain regulatory approval for its pharmaceutical products or that such products, if approved for use, will be successful in the market place. Level 5, 160 Queen Street  T +61 3 9660 4900             www.clinuvel.com Melbourne, Victoria 3000F +61 3 9660 4999 Australia

Read More
 2015-07-01

SUMMARY SCENESSE® Risk Management Plan infrastructure nearing finalisation EPP expert centre training commences this week Leatherhead, UK and Melbourne, Australia Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced an update on the commercial distribution of its drug SCENESSE® (afamelanotide 16mg) for erythropoietic protoporphyria (EPP) across Europe. SCENESSE® was granted marketing authorisation by the European Commission for adults diagnosed with EPP on December 22, 2014. A number of post-authorisation commitments were agreed with the European Medicines Agency (EMA) under a long-term risk management plan (RMP) for SCENESSE®. The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) is scheduled to complete the final review of commitments relating to the distribution of SCENESSE® in September 2015. POST-AUTHORISATION COMMITMENTSThe RMP requires that patients receiving SCENESSE® are monitored for long-term safety. This includes the establishment of a Centralised European EPP Disease Registry and a post-authorisation safety study (PASS) of all patients receiving SCENESSE®. PRAC is currently finalising its review of the Disease Registry. In accordance with relevant European legislation1 the Disease Registry is set up allowing trained physicians to enter anonymised medical information on the real-time use of SCENESSE®. Clinuvel is responsible for providing biannual safety reports to the EMA for the first 24 months following product release. An independent Governance Board and Data and Safety Monitoring Board oversee the management of the Disease Registry.EUROPEAN TRAINING OF EPP EXPERT PHYSICIANSAs part of its European regulatory commitments, Clinuvel is required to adequately train expert physicians and their professional staff prior to prescribing SCENESSE®.The first European EPP Expert Convention takes place on June 5 in Paris. In total 33 physicians from 23 different centres across 15 countries are represented. This convention will instruct expert physicians and specialists on the use of the Disease Registry and the administration of SCENESSE®. Clinuvel will host a number of these expert meetings concomitant with the European distribution of SCENESSE®.DISTRIBUTION OF SCENESSE® IN ITALY AND SWITZERLANDSpecial Access Schemes which started in 2010 allow the distribution of SCENESSE® in Italy and Switzerland.  A recent publication reported on the longer term follow up of 115 EPP patients from these programs.2 COMMENTARY“My team is putting all the required processes in place in accordance with the EMA’s principles and we have progressed our distribution of SCENESSE®,” Clinuvel’s Acting Chief Scientific Officer, Dr Dennis Wright said. “The extent of the interest shown in prescribing SCENESSE® for EPP has exceeded our expectations for today’s convention.” “It is a considerable undertaking to put in place the quality management systems and processes required by the EMA,” Clinuvel’s Director Clinical Affairs Dr Emilie Rodenburger said. “While EMA progress is taking longer than we wish for, our team is clearly excited by the approaching landmark of treating EPP patients.”“The past months have demonstrated clinical demand from EPP patients, especially from countries where Clinuvel had not been before,” Dr Rodenburger said.REFERENCES1 The European Convention on Human Rights, Article 8 of the Charter of Fundamental Rights of the European Union, and the Data Protection Directive 95/46/EC.2 Biolcati G, Marchesini E, Sorge F, Barbieri L, Schneider-Yin X and Minder E (2015). “Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria.” Brit J Dermatol. 172(6):1601-12. E-pub Dec 13, 2014. Available online: http://onlinelibrary.wiley.com/doi/10.1111/bjd.13598/pdf. - End - Media enquiries Lachlan Hay, Clinuvel (UK) Ltd. +44 1372 860 765    This email address is being protected from spambots. You need JavaScript enabled to view it. Nick Miles, Cabinet Privé de Conseils s.a. +41 22 321 4540    This email address is being protected from spambots. You need JavaScript enabled to view it. Ted Agne, The Communications Strategy Group Inc. +1 718 631 3117   This email address is being protected from spambots. You need JavaScript enabled to view it. Investor enquiries   This email address is being protected from spambots. You need JavaScript enabled to view it. About Clinuvel Pharmaceuticals Limited Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe disorders. With its unique expertise in understanding the interaction of light and human skin, the company has identified patient populations with a clinical need for photoprotection and another population with a need for repigmentation. These patient groups range in size from 5,000 to 45 million. Clinuvel’s lead compound, SCENESSE® (afamelanotide 16mg), a first-in-class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe, and has been approved by the European Commission for treating adults with EPP. Headquartered in Melbourne, Australia, Clinuvel has operations in Europe, the US and Singapore. For more information go to  http://www.clinuvel.com. Clinuvel is an Australian biopharmaceutical company focussed on developing its drug SCENESSE® (afamelanotide 16mg) for a range of clinical disorders with unmet need. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following: actual results may and often will differ materially from these forward-looking statements; no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for SCENESSE® can or will be achieved; no assurances can be given by Clinuvel that, even if its development programme for SCENESSE® is successful, it will obtain regulatory approval for its pharmaceutical products or that such products, if approved for use, will be successful in the market place. Level 5, 160 Queen Street  T +61 3 9660 4900             www.clinuvel.com Melbourne, Victoria 3000F +61 3 9660 4999 Australia

Read More
 2015-06-05

Singaporean subsidiary VALLAURIX completes preliminary evaluation of VLRX001 SUMMARY Clinuvel expands pipeline with VLRX001 targeting skin disorders First therapeutic target: vitiligo (depigmentation disorder) as maintenance therapy following SCENESSE® (afamelanotide 16mg) Innovation is the result of collaboration between Clinuvel and the international research community Proprietary technology of VALLAURIX PTE LTD, a majority-owned Clinuvel subsidiary Recent clinical research has demonstrated a renaissance in the demand for novel melanocortin molecules Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA: UR9; ADR: CLVLY) today announced that its Singaporean subsidiary VALLAURIX PTE LTD has successfully completed initial in-vitro development of VLRX001, an innovative melanocortin analogue. VLRX001 is an addition to Clinuvel’s product pipeline alongside CUV9900 and SCENESSE® (afamelanotide 16mg), which was recently granted marketing authorisation by the European Commission for the rare disease erythropoietic protoporphyria (EPP). CLINICAL USEFormulation work will focus on the development of VLRX001 for topical self-administration by patients. The transdermal product will initially be evaluated as adjuvant maintenance therapy in the depigmentation disorder vitiligo. SCENESSE® is currently being evaluated as a subcutaneous medicinal product for repigmentation in vitiligo patients. Clinuvel published its first vitiligo results in 2012/13. RATIONALE FOR INNOVATIONThe VLRX001 development work was undertaken through Clinuvel’s majority owned Singaporean subsidiary, VALLAURIX and has leveraged the knowledge gained from long term experience with the clinical use of SCENESSE®. It has long been acknowledged that melanocortins have a ubiquitous application in medicine. A renaissance in the demand for novel melanocortin molecules has been seen in clinical research, with more than 400 peer reviewed publications on the use of melanocortins over the past 24 months. KNOWHOW AND INTELLECTUAL PROPERTYLong term collaboration between Clinuvel’s scientific teams and research groups at prestigious institutes and universities led to the innovation of VLRX001. VALLAURIX was able to harness the knowhow in melanocortins from IP and data generated in pharmacology studies and clinical use of SCENESSE® by Clinuvel’s global teams. Overall, the development of VLRX001 is part of Clinuvel’s life cycle management of its portfolio of products to ensure long term use and value of its technology and assets. Patent applications on VLRX001 have been filed in the commercially relevant jurisdictions. Clinuvel will hold all rights to the final product and indications through VALLAURIX. Formulation work will commence this year. VLRX001 is the second novel molecule to be evaluated by VALLAURIX. The first, CUV9900, has been developed as the first reference standard for evaluating pharmacological properties such as binding affinity, potency and cellular signalling. NOVEL PHARMACOLOGYVLRX001 is an addition to the family of melanocortin analogues which provoke increased and prolonged cellular activity. It contains a specific peptide sequence, designed to make it less susceptible to degradation than physiologic (natural) alpha-melanocyte stimulating hormone (α-MSH). COMMENTARY“Many biotech and pharmaceutical companies commence the development of novel products but the complexity of human biological response and regulatory pathway see many of these fail along the road,” Clinuvel’s Acting Chief Scientific Officer, Dr Dennis Wright said. “It is a privilege to be part of a team which has delivered success through SCENESSE®. “With VLRX001 we now have a logical follow-on product which we hope will act synergistically and be complementary to SCENESSE® in the treatment of vitiligo, a disease which is notoriously difficult to treat and deserves a range of therapeutic approaches,” Dr Wright said. “Over the past year the management of Clinuvel have successfully transformed the Company from being an R&D house with a prospective regulatory outcome, to one with a commercial product lending its validation to second generation technology with wide applications,” Clinuvel’s Chairman, Mr Stan McLiesh said. “It has been Clinuvel’s key objective to retain the proprietary rights to the new technology. “Our scientific and commercial progress stems from many years of interaction and dialogue with physicians and patients, and our teams have consistently taken a staunch approach to the opinions of global experts. I am certain that the corollary of Clinuvel’s work will result not only in clinical worth but in sustained shareholder value even in Australia, a market still lacking full appreciation of its biotech companies,” Mr McLiesh said. CLINUVEL'S PIPELINE [See PDF announcement] REFERENCES Bohm M et al (2006). Melanocortin Receptor Ligands: New Horizons for Skin Biology and Clinical Dermatology. J Inv Dermatol. 126:1966-1975. Graham A, Westerhof W & Thody AJ (1999). The Expression of α-MSH by Melanocytes is Reduced in Vitiligo. Annals NY Acad Sci. 885:470-473. Lim, HW et al (2015). Afamelanotide and Narrowband UV-B Phototherapy for the Treatment of Vitiligo. JAMA Dermatol. 151(1): 42-50. E-Pub Sept 17, 2014. Luger TA & Bohm M (2015). An α-MSH Analog in Erythropoietic Protoporphyria. J Inv Dermatol. 135:929-931. ` Luger TA & Brzoska T (2007). Alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Ann Rheum Dis. 66 (Suppl 3):iii52-55. Biolcati G et al (2014). Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. Br J Dermatol. E-Pub Dec 13. - End - Media enquiries Lachlan Hay, Clinuvel (UK) Ltd. +44 1372 860 765    This email address is being protected from spambots. You need JavaScript enabled to view it. Nick Miles, Cabinet Privé de Conseils s.a. +41 22 321 4540    This email address is being protected from spambots. You need JavaScript enabled to view it. Ted Agne, The Communications Strategy Group Inc. +1 718 631 3117   This email address is being protected from spambots. You need JavaScript enabled to view it. Investor enquiries   This email address is being protected from spambots. You need JavaScript enabled to view it. About Clinuvel Pharmaceuticals Limited Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) is a global biopharmaceutical company focused on developing drugs for the treatment of a range of severe disorders. With its unique expertise in understanding the interaction of light and human skin, the company has identified patient populations with a clinical need for photoprotection and another population with a need for repigmentation. These patient groups range in size from 5,000 to 45 million. Clinuvel’s lead compound, SCENESSE® (afamelanotide 16mg), a first-in-class drug targeting erythropoietic protoporphyria (EPP), has completed Phase II and III trials in the US and Europe, and has been approved by the European Commission for treating adults with EPP. Headquartered in Melbourne, Australia, Clinuvel has operations in Europe, the US and Singapore. For more information go to  http://www.clinuvel.com. Clinuvel is an Australian biopharmaceutical company focussed on developing its drug SCENESSE® (afamelanotide 16mg) for a range of clinical disorders with unmet need. Pharmaceutical research and development involves long lead times and significant risks. Therefore, while all reasonable efforts have been made by Clinuvel to ensure that there is a reasonable basis for all statements made in this document that relate to prospective events or developments (forward-looking statements), investors should note the following: actual results may and often will differ materially from these forward-looking statements; no assurances can be given by Clinuvel that any stated objectives, outcomes or timeframes in respect of its development programme for SCENESSE® can or will be achieved; no assurances can be given by Clinuvel that, even if its development programme for SCENESSE® is successful, it will obtain regulatory approval for its pharmaceutical products or that such products, if approved for use, will be successful in the market place. Level 5, 160 Queen Street  T +61 3 9660 4900             www.clinuvel.com Melbourne, Victoria 3000F +61 3 9660 4999 Australia

Read More
 2015-05-05

Clinuvel Stock Ticker

Clinuvel Latest News

New England Journal of Medicine publishes pivotal Phase III SCENESSE® studies

Clinuvel Pharmaceuticals Ltd today announced that results from its pivotal Phase III studies of SCENESSE® (afamelanotide 16mg) in the orphan genetic disorder erythropoietic protoporphyria (EPP) have been published in the New England Journal of Medicine (NEJM, 2015, vol 375: 48-59, publisher’s embargo lifted at 17:00 EST, July 1). The Company's full ASX announcement ...

Vitiligo Latest News

SCENESSE® vitiligo study results published in JAMA Dermatology

Results from Clinuvel's first Phase II study of SCENESSE® (afamelanotide 16mg) have been published in the peer-reviewed journal JAMA Dermatology. Access the article abstract Read Clinuvel's release Watch an interview with CUV102 investigator Dr Henry Lim...

Clinuvel Spotlight

Company History

The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide 16mg), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology and has spent over A$20million optimising the chemistry of afamelanotide (the active ingredient in SCENESSE...

Clinuvel Blog Posts

In 2010, Clinuvel announced that it would commence a clinical trial of a new drug for vitiligo. In late 2012 the first treatment results...

The biennial Porphyrins & Porphyrias conference is the only international meeting of global key opinion leaders on the group of...

Today, February 28, marks Rare Disease Day: an annual event to help highlight the effects of rare diseases on individuals, families and the...

Clinuvel Webcasts

What can vitiligo patients do? - Lee Thomas and Dr ...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

The future of vitiligo treatment - Lee Thomas and D...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Vitiligo trials of SCENESSE® - Lee Thomas and Dr Ph...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Quick Links